Title: Effects of Irbesartan in induced Parkinson’s Disease in Mice
Abstract: Irbesartan (Irb) is an angiotensin receptor blockader (ARBs) and agonist of peroxisome proliferator-activated receptor (PPAR) γ, which owns inhibitory effects of inflammation, oxidation, and apoptosis, manipulation of the renin-angiotensin system results in dawdling nigrostriatal damage. The objective of the study is to explore the neuroprotective effect of Irbesartan on the dopaminergic neurons in the substantia nigra pars compacta (SNpc) in a 1-Methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine hydrochloride (MPTP) mouse model of Parkinson’s disease (PD). Male mice were kept separately into 5 groups control (normal), model, classical treatment, oleic and Irbesartan group, the control group received N/S intraperitoneally (ip) (10 mL/kg) for 5 days, PD induced by MPTP IP (30 mg/kg) daily for 5 days for the all group except control, then all animal from day 6 to day 21 received a single oral dose of the following: control group and PD induced group (model or MPTP group) N/S (20 mL/kg), oleic acid 0.1 mL, Classical treatment (L-dopa/Carbidopa) [(250/25) mg/kg] and Irb (50 mg/kg) daily for 21 days. The behavioral changes of mice were assessed using a pole-climbing test. The levels of dopamine (DA), DA receptor type 2 (D2 receptors), caspase-3 and malondialdehyde (MDA) in the striatum were assayed with the help of the immunohistochemical method in substantia nigra. The results obtained from pole-climbing time in all test groups which performed each 5 days of the experiment (day 5, 10, 15, and 20) at day 5 revealed there were no significant change in time than model group (p > 0.05), at day 10,15 and 20 there were significant decrement in time for Irb group compared to model group (p less than 0.001). The DA receptors and MDA decreased significantly in L-dopa, and Irb groups in compared to model group (p less than 0.001), DA level were significantly increased in L-dopa and Irb in compared to model group (p less than 0.001), while caspase-3 were significantly reduced in Irb in compared to L-dopa and model groups (p less than 0.001). The result demonstrates the neuroprotective effect of Irb in PD’s experimental model, suggesting Irb probably a candidate neuroprotective drug for human PD patients.
Publication Year: 2021
Publication Date: 2021-03-25
Language: en
Type: article
Access and Citation
Cited By Count: 1
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot